Autres domaines


SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role - 19/12/20

Doi : 10.1016/j.biopha.2020.110947 
Ahmad Ud Din a, 1, Maryam Mazhar b, 1, Muhammed Waseem c, Waqar Ahmad d, a, Asma Bibi e, Adil Hassan f, Niaz Ali g, Wang Gang a, Gao Qian a, Razi Ullah f, Tariq Shah h, Mehraj Ullah i, Israr Khan j, Muhammad Farrukh Nisar k, Jianbo Wu a,
a Drug Discovery Research Center, Southwest Medical University, Luzhou, 646000, Sichuan, China 
b Research Center of Integrated Traditional Chinese and Western Medicine, Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China 
c State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, College of Horticulture, South China Agricultural University, Guangzhou, 510642, China 
d College of Marine Life Sciences and Institute of Evolution and Marine Biodiversity, Ocean University of China, Qingdao, 266003, China 
e Institute of Zoonosis Anhui Medical University, Hefei Anhui, 230032, China 
f Key Laboratory for Bio-rheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants Bioengineering College of Chongqing University, Chongqing, 400030, China 
g State Key Laboratory for Conservation and Utilization of Subtropical Agro-bio-resources, College of Life Science and Technology, Guangxi University, 100 Daxue Road, Nanning, 530004, Guangxi, China 
h State Key Laboratory of Grassland Agro-Ecosystem, School of Life Sciences, Lanzhou University, Lanzhou, 730000, China 
i Department of Biotechnology School of Fermentation Engineering Tianjin University of Science and Technology China, China 
j School of Life Sciences, Lanzhou University, China 
k Department of Physiology and Biochemistry, Cholistan University of Veterinary and Animal Sciences (CUVAS), Bahawalpur, 63100, Pakistan 

Corresponding author at: Drug Discovery Research Center, Southwest Medical University, Luzhou, 646000, China.Drug Discovery Research CenterSouthwest Medical UniversityLuzhou646000China

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Graphical abstract

Le texte complet de cet article est disponible en PDF.


Gut microbial diversity dysbiosis leads to increased death in COVID-19.
High death tool in COVID-19 is due to microbiome disturbance in co-morbid patients.
More deaths in ICU Individual seems to be because of microbiome dysbiosis.
Probiotics can be a Supplementary Therapy to decrease death tool in COVID-19.

Le texte complet de cet article est disponible en PDF.


In December 2019, a pneumonia outbreak of unknown etiology was reported which caused panic in Wuhan city of central China, which was later identified as Coronavirus disease (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by the Chinese Centre for Disease Control and Prevention (CDC) and WHO. To date, the SARS-CoV-2 spread has already become a global pandemic with a considerable death toll. The associated symptoms of the COVID-19 infection varied with increased inflammation as an everyday pathological basis. Among various other symptoms such as fever, cough, lethargy, gastrointestinal (GI) symptoms included diarrhea and IBD with colitis, have been reported. Currently, there is no sole cure for COVID-19, and researchers are actively engaged to search out appropriate treatment and develop a vaccine for its prevention. Antiviral for controlling viral load and corticosteroid therapy for reducing inflammation seems to be inadequate to control the fatality rate. Based on the available related literature, which documented GI symptoms with diarrhea, inflammatory bowel diseases (IBD) with colitis, and increased deaths in the intensive care unit (ICU), conclude that dysbiosis occurs during SARS−COV-2 infection as the gut-lung axis cannot be ignored. As probiotics play a therapeutic role for GI, IBD, colitis, and even in viral infection. So, we assume that the inclusion of studies to investigate gut microbiome and subsequent therapies such as probiotics might help decrease the inflammatory response of viral pathogenesis and respiratory symptoms by strengthening the host immune system, amelioration of gut microbiome, and improvement of gut barrier function.

Le texte complet de cet article est disponible en PDF.

Keywords : COVID-19, IBD, Colitis, ICU, Gut microbiome, Probiotics


© 2020  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 133

Article 110947- janvier 2021 Retour au numéro
Article précédent Article précédent
  • The involvement of noncanonical Wnt signaling in cancers
  • Yongfeng Chen, Zhengxi Chen, Yin Tang, Qian Xiao
| Article suivant Article suivant
  • Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota
  • Hai-Yu Zhang, Jia-Xing Tian, Feng-Mei Lian, Min Li, Wen-Ke Liu, Zhong Zhen, Jiang-Quan Liao, Xiao-Lin Tong

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.